Charles River Laboratories International (CNSX:CRL) and Integral Diagnostics (ASX:IDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.
Valuation & Earnings
This table compares Charles River Laboratories International and Integral Diagnostics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Charles River Laboratories International | N/A | N/A | N/A | N/A | N/A |
Integral Diagnostics | $314.82 million | 0.00 | $32.18 million | A$0.16 | N/A |
Integral Diagnostics has higher revenue and earnings than Charles River Laboratories International.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Charles River Laboratories International and Integral Diagnostics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Charles River Laboratories International | 0 | 0 | 0 | 0 | N/A |
Integral Diagnostics | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Charles River Laboratories International and Integral Diagnostics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Charles River Laboratories International | N/A | N/A | N/A |
Integral Diagnostics | N/A | N/A | N/A |
Summary
Integral Diagnostics beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.